Bellerophon Therapeutics, Inc.: Nasdaq/NYSE listing notice — Bellerophon to dissolve and liquidate after Nasdaq delisting; trading suspended Oct 16

Bellerophon Therapeutics, Inc.

Nasdaq will suspend trading of BLPH common stock at open on Oct 16, 2023 after company failed to meet listing conditions.
Board approved a plan of liquidation and dissolution on Oct 12, 2023, subject to stockholder approval at a special meeting.
Company will cease business operations and distribute remaining assets to stockholders after paying all claims and obligations.
Stockholders are not entitled to appraisal rights; stock will be cancelled after final distributions.

item 3.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Bellerophon Therapeutics, Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5550(a)(2)).

Exchange: nasdaq
Notice: delisting notice
Rules: 5101, 5550(a)(2)

Exact text from the filing

October 12, 2023, the Company notified the Panel that it will not be able to meet the conditions of the Panel’s decision. Accordingly, on October 12, 2023, the Staff notified the Company that it determined to delist the Company’s shares of common stock from the Nasdaq Capital Market and that trading in the Company’s shares will be suspended at the open of trading on Monday October 16, 2023.

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-23-108988

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.